VNDA — Vanda Pharmaceuticals Income Statement
0.000.00%
- $355.59m
- -$38.55m
- $192.64m
- 79
- 47
- 86
- 81
Annual income statement for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 227 | 248 | 269 | 254 | 193 |
Cost of Revenue | |||||
Gross Profit | 203 | 225 | 243 | 230 | 178 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 204 | 221 | 227 | 248 | 207 |
Operating Profit | 22.8 | 27.2 | 42.2 | 6.33 | -14 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 29 | 31.7 | 42.4 | 11.3 | 6.34 |
Provision for Income Taxes | |||||
Net Income After Taxes | 116 | 23.3 | 33.2 | 6.28 | 2.51 |
Net Income Before Extraordinary Items | |||||
Net Income | 116 | 23.3 | 33.2 | 6.28 | 2.51 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 116 | 23.3 | 33.2 | 6.28 | 2.51 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.11 | 0.515 | 0.855 | 0.11 | 0.044 |